1. Introduction {#sec1}
===============

Comorbidity adversely impacts the treatment \[[@B1]--[@B7]\] and outcomes \[[@B1], [@B3], [@B6], [@B8]--[@B22]\] of breast cancer, especially in older patients. For instance, studies have shown that breast cancer patients with previously identified comorbidity are less likely to receive adjuvant chemotherapy \[[@B2], [@B4], [@B5]\] and have higher mortality \[[@B8]\]. Many such studies from the United States are based on the Surveillance, Epidemiology, and End Results cancer registry linked to health insurance claims (SEER-Medicare) \[[@B1], [@B2], [@B5], [@B6], [@B17]--[@B20]\], where a common approach is first to identify conditions appearing in claims prior to cancer and then to use these conditions to construct a National Cancer Institute (NCI) Comorbidity Index \[[@B23]\], which is an adaptation of the Charlson index (CCI) \[[@B24]\].

Most studies based on SEER-Medicare include some measures of comorbidity, and in a random sample of all SEER-Medicare studies published between 2006 and 2011, 23/30 (77%) included the NCI Comorbidity Index. One important limitation of this index, however, is that it ignores conditions that are undetected in claims until after cancer is diagnosed. Recently, we examined the incidence of undetected comorbidity in breast cancer \[[@B25]\] and found that many chronic conditions included in the NCI Comorbidity Index, such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), diabetes, and cerebrovascular disease (CVD), remained undetected in claims until 1--3 months after cancer.

Undetected comorbidity could have additional implications for breast cancer treatment and outcomes. Therefore, in this study we sought to describe risk factors for comorbidity that remained undetected until breast cancer, and to assess the added impact of undetected comorbidity on breast cancer treatment and outcomes.

2. Methods {#sec2}
==========

2.1. Data {#sec2.1}
---------

Presently SEER-Medicare \[[@B26]\] includes all Medicare-eligible persons from 16 of the 17 SEER registries through 2005 and their Medicare claims for Part A (inpatient) and Part B (outpatient and physician services) through 2007.

2.2. Patients {#sec2.2}
-------------

Patients were included if they were diagnosed with breast cancer between 2001-01-01 and 2005-12-31, had only one primary cancer diagnosed, and had at least 12 months of Medicare Part A and Part B coverage prior to cancer. They were excluded for the following reasons: male breast cancer, cancer diagnosed before age 65, diagnosis made by death certificate or autopsy, death within the first month following diagnosis, or Medicare enrollment less than 12 months before diagnosis. Patients were followed up from 12 months before cancer until the end of the claims period (2007-12-31) or death, whichever came first. Since SEER reports only the month of cancer diagnosis, the first day of that month was assigned as the date of diagnosis.

### 2.2.1. Variables {#sec2.2.1}

Patients were described according to their demographic, clinical, and socioeconomic characteristics \[[@B26], [@B27]\]. SEER does not include measures of performance status, such as Eastern Cooperative Oncology Group. Instead, we used Medicare claims to identify several indictors of poor performance status, including the use of oxygen and related respiratory therapy supplies, wheelchair and supplies, home health agency services, and skilled nursing facility admissions, all from 12 months before until 30 days after breast cancer diagnosis \[[@B28]\].

The SEER-Medicare dataset contains information from the 2000 US Census, reported at the tract level in which the patient lives, for the percent of the population living in poverty and the percent of those aged ≥25 years with some college. We used these as indicators of the socioeconomic status of individual patients in the cohort.

### 2.2.2. Comorbidity {#sec2.2.2}

We constructed two indices of comorbidity. In SEER-Medicare, the gold standard for documenting the presence of comorbidity prior to cancer is the NCI Comorbidity Index \[[@B23]\], which is usually constructed based on claims from 12 months to one month before cancer diagnosis. Diagnosis and procedure codes are used to identify the 15 noncancer comorbidities in the CCI \[[@B24]\]. A weight is then assigned to each condition, and the weights are summed to obtain the index score for each patient. We followed this approach to capture comorbidity detected prior to cancer and classified patients as having a score =0, 1, or ≥2.

We applied the same algorithms used in the NCI Comorbidity Index to construct an index of undetected comorbidity, which was based on claims from the month of cancer diagnosis up to two months after. For each patient, conditions identified prior to cancer were excluded from the undetected comorbidity index. If chemotherapy or radiation began within three months following cancer diagnosis, the observation period for the undetected comorbidity index was truncated at that time to minimize the risk of misclassifying treatment-related adverse events as undetected conditions. As above, patients were classified as having a score = 0, 1, or ≥2. Since the minimum weight assigned to any condition in either index is one (1), for clarity the term "≥ 1 condition/comorbidity" is used in the Results to describe patients with a score on either the previously detected or undetected comorbidity index of ≥1.

### 2.2.3. Adjuvant Chemotherapy {#sec2.2.3}

Adjuvant chemotherapy was identified based on Healthcare Common Procedure Coding (HCPCS) "J" codes as recommended by the NCI \[[@B29]\]. The first claim for chemotherapy had to appear within 180 days of cancer diagnosis for the patient to be classified as having received chemotherapy.

2.3. Mortality {#sec2.3}
--------------

The date of death was assigned by using the Medicare date if available. When the Medicare date was missing but the SEER date was available, the SEER date was used. All other patients were assumed to be alive at the end of the observation period. The cause of death was classified as cancer or other cause.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Multivariable analyses were performed to examine risk factors for undetected comorbidity, as well as associations between undetected comorbidity, adjuvant chemotherapy, and mortality. Both indices of comorbidity were included in analyses of treatment and mortality to assess the incremental impact of undetected comorbidity. The multivariable analysis of adjuvant chemotherapy was limited to those with stage I--III disease \[[@B5]\]. All multivariable survival analyses included only those who survived at least 3 months after cancer diagnosis. Final models were selected through a process of forward, stepwise regression, taking into account statistical significance, interactions among covariables, and whether a nonstatistically significant finding was informative. In almost all instances, at least one level of each variable included in the final model was statistically significantly different from the reference category of that variable. In all instances, prior comorbidity and previously undetected comorbidity were included in the final multivariable model. However, we compared the magnitude and significance of the coefficients on the previously undetected comorbidity in models that included versus excluded prior comorbidity as a covariable to assess the level of colinearity between these two.

3. Results {#sec3}
==========

There were 61,002 patients in the final cohort, of whom 6,184 (10%) had ≥1 undetected comorbidity. The mean (standard deviation) age was 76.0 (6.8), 54.6% were aged \>75 years, 61% were diagnosed with *in situ* or stage I disease, 14% had ≥1 indicator of poor performance, and 33% had ≥1 comorbidity detected prior to cancer ([Table 1](#tab1){ref-type="table"}). Those with ≥1 undetected comorbidity also were more likely to have ≥1 condition detected prior to cancer.

3.1. Undetected Comorbidity {#sec3.1}
---------------------------

Among the 6,184 patients with ≥1 undetected comorbidity, there were a total of 7,593 conditions. The most common were COPD (33% \[2,023/6,184\] of patients), CHF (18%), diabetes (18% without complications; 4% with complications), myocardial infarction (14%), and CVD (10%). In multivariable logistic regression, factors associated with having ≥1 undetected condition were older age, ≥1 comorbidity detected prior to cancer, ≥1 indicator of poor performance status, advanced stage, histological grade, living in a census tract with more poverty, and living in an urban area. Other race/ethnicity (compared to white) and later year of cancer diagnosis were associated with lower odds of having ≥1 undetected condition ([Table 2](#tab2){ref-type="table"}).

3.2. Chemotherapy {#sec3.2}
-----------------

In multivariable analysis, undetected comorbidity was associated with lower adjusted odds of receiving adjuvant chemotherapy (Odds Ratio (OR) = 0.81, 95% Confidence Interval (CI) 0.73--0.90, *P* \< 0.0001; OR = 0.38, 95% CI 0.30--0.49, *P* \< 0.0001, for undetected comorbidity index score 1 or ≥2, resp.) ([Table 3](#tab3){ref-type="table"}). Other factors associated with lower odds were older age, later year of diagnosis, having ≥2 conditions detected prior to cancer, being either estrogen and/or progesterone receptor positive, and living in a census tract with \>12% poverty. Factors associated with higher odds included advanced stage and higher grade.

3.3. Survival {#sec3.3}
-------------

Overall, there were 13,208 (22% of cohort) deaths: 5,191 (39% of all deaths) due to cancer; 5,823 (44%) due to other causes; and (17%) unspecified. Among those with ≥1 undetected comorbidity, 42% (2,575) died during the observation period compared to 19% (10,633) of those with no undetected conditions, and the unadjusted mortality rate was significantly higher (*P* \< 0.0001) ([Figure 1](#fig1){ref-type="fig"}).

In multivariable survival analysis, having undetected comorbidity was associated with increased all-cause mortality (Hazard Ratio (HR) = 1.45, 95% CI 1.38--1.53, *P* \< 0.0001; HR = 2.38, 95% CI 2.18--2.60, *P* \< 0.0001, for undetected comorbidity index score 1 or ≥2, resp.), cancer mortality (HR = 1.32 and HR = 1.67 for score 1 or ≥2), and other-cause mortality (HR = 1.58 and HR = 3.31 for score 1 or ≥2) ([Table 4](#tab4){ref-type="table"}). In most instances, coefficients for undetected comorbidity were comparable to or larger than those for comorbidity detected prior to cancer.

3.4. Models with versus without Previously Detected Comorbidity {#sec3.4}
---------------------------------------------------------------

There was little difference in the magnitude and significance of the coefficients for the previously undetected comorbidity for multivariable models that included versus excluded prior comorbidity as a covariable. For instance, the coefficients for the chemotherapy model were 0.80 and 0.37 for undetected comorbidity scores of 1 and ≥2, respectively, in the model that *excluded* prior comorbidity compared to 0.81 and 0.38 in the model that *included* prior comorbidity ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

We conducted an observational cohort study using SEER-Medicare to describe risk factors for comorbidity that remained undetected until breast cancer and to assess the added impact of undetected comorbidity on breast cancer treatment and outcomes. Advanced age, later stage diagnosis, poor performance status, presence of comorbidity identified prior to cancer, and poverty all were associated with increased risk of undetected comorbidity. The strong monotonic association with cancer stage, as well as the association with poverty, suggests the existence of shared risk factors, such as poor health system contact prior to cancer diagnosis, \[[@B30], [@B31]\] resulting in delayed detection of both cancer and other underlying chronic conditions including COPD, CHF, and diabetes. One important implication of our study is that those with other established risk factors for poor outcomes in breast cancer, including advanced age, later stage, and poor performance status, also are at greatest risk for undetected comorbidity.

Patients with undetected comorbidity were less likely to receive adjuvant chemotherapy. Furthermore, the effect sizes were larger for undetected comorbidity than for comorbidity detected prior to cancer. For example the Odds Ratio for an undetected comorbidity index score ≥2 was 0.38 compared to 0.74 for a score ≥2 on the index of conditions prior to cancer. Since identification of conditions was based on claims for medical services, one hypothesis is that undetected conditions were more severe because they had not been treated. Others have speculated that one way comorbidity can influence treatment and outcomes in cancer is by distracting the healthcare team from the appropriate management of both \[[@B32]\] cancer and other conditions. The fact that effect sizes were larger for undetected conditions suggest that these may pose greater challenges for the healthcare team than those that have a history of being treated prior to cancer.

Undetected comorbidity also was associated with increased overall cancer and other-cause mortality. The impact on other-cause mortality was larger than on cancer mortality. However, all six HRs in the three survival analyses were highly statistically significant, and, in general, HRs for undetected comorbidity were larger than those for comorbidity detected prior to cancer. Again, this supports the hypothesis that undetected comorbidity may be more severe and that it may pose greater challenges to the healthcare team than conditions appearing in claims and, by implication, treated prior to cancer.

It is likely that the impact of undetected comorbidity on cancer mortality is partially explained by its direct impact on the likelihood of receiving adjuvant chemotherapy. The link between adjuvant chemotherapy and survival in breast cancer is well established, and adjuvant chemotherapy was not included in our survival analyses to avoid over adjustment of the models.

Our study has several limitations. First, as discussed above, we cannot rule out the possibility that unobserved factors may have confounded observed associations between the presence of undetected comorbidity and several of the observed risk factors, notably cancer stage at diagnosis. Second, both comorbidity indices in our study are based on claims and consequently have less-than-perfect sensitivity and specificity for the conditions of interest. Therefore, conditions that simply were not found in claims prior to cancer due to limitations of the algorithms in the NCI Comorbidity Index, but which actually had been detected and possibly treated at an earlier date, may have been misclassified as undetected. Third, since SEER includes only the month and not the day of cancer diagnosis, we elected to assign the first day of the month as the date of cancer diagnosis. Had we elected to assign the last day of the month, all conditions classified as previously undetected by virtue of first appearing in the month of cancer diagnosis would have been reclassified as previously detected.

5. Conclusions {#sec5}
==============

Limitations notwithstanding, our findings indicate that those patients with established risk factors for poor outcomes in breast cancer, including advanced age, later stage, and poor performance status, also are at greatest risk for undetected comorbidity. Furthermore, undetected comorbidity appears to confer greater additional risk of poor outcomes than comorbidity detected prior to cancer, suggesting that it may be more severe and that it may pose additional challenges to the healthcare team. However, these hypotheses would require further investigation.
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###### 

Patient characteristics.

  ------------------------------------------------------------------------------------------------------------------------------------------
                                                                 Index of undetected comorbidity                                  
  ----------------------------------------------------- -------- --------------------------------- -------- ------ ------- ------ ----------
  Age at cancer diagnosis (years)                                                                                                   

   66--70                                               12,361   20.3                              11,412   20.8   949     15.4   \<0.0001

   71--75                                               15,368   25.2                              14,036   25.6   1,332   21.5   

   76--80                                               15,108   24.8                              13,576   24.8   1,532   24.8   

   \>80                                                 18,165   29.8                              15,794   28.8   2,371   38.3   

  Race/ethnicity                                                                                                                   

   White                                                52,270   85.7                              47,048   85.8   5,222   84.4   \<0.0001

   Black                                                4,188    6.9                               3,639    6.6    549     8.9    

   Hispanic                                             2,249    3.7                               2,016    3.7    233     3.8    

   Other                                                2,295    3.8                               2,115    3.9    180     2.9    

  Year of cancer diagnosis                                                                                                         

   2001                                                 12,660   20.8                              11,322   20.7   1,338   21.6   0.12

   2002                                                 12,452   20.4                              11,166   20.4   1,286   20.8   

   2003                                                 12,086   19.8                              10,845   19.8   1,241   20.1   

   2004                                                 11,929   19.6                              10,765   19.6   1164    18.8   

   2005                                                 11,875   19.5                              10,720   19.6   1155    18.7   

  Index of prior comorbidity score\                                                                                                
  (NCI Comorbidity Index)                                                                                                         

   0                                                    41,001   67.2                              37,365   68.2   3,636   58.8   \<0.0001

   1                                                    13,480   22.1                              11,952   21.8   1,528   24.7   

   ≥2                                                   6,521    10.7                              5,501    10.0   1020    16.5   

  Stage at diagnosis                                                                                                               

    *In*   *situ*                                       10,167   16.7                              9,618    17.6   549     8.8    \<0.0001

   I                                                    26,754   43.9                              24,578   44.8   2,176   35.1   

   II                                                   17,165   28.1                              15,080   27.5   2,085   33.7   

   III                                                  4,096    6.7                               3,428    6.3    668     10.8   

   IV                                                   2,820    4.6                               2,114    3.9    706     11.4   

  Estrogen (ER) and progesterone (PR) receptor status                                                                              

   ER and PR positive                                   31,419   51.5                              28,347   51.7   3,072   49.7   \<0.0001

   ER or PR positive                                    8,081    13.3                              7,203    13.1   878     14.2   

   ER and PR negative                                   7,165    11.8                              6,353    11.6   812     13.1   

   Unknown/missing                                      14,337   23.5                              12,915   23.6   1,422   23.0   

  Histological grade                                                                                                               

   1                                                    12,419   20.4                              11,403   20.8   1,016   16.4   \<0.0001

   2                                                    23,407   38.4                              21,090   38.5   2,317   37.5   

   3                                                    15,291   25.1                              13,528   24.7   1,763   28.5   

   4                                                    1,881    3.1                               1,710    3.1    171     2.8    

   Missing/unknown                                      8,004    13.1                              7,087    12.9   917     14.8   

  Indicators of poor performance                                                                                                   

   0                                                    52,460   86.0                              47,599   86.8   4,861   78.6   \<0.0001

   ≥1                                                   8,542    14.0                              7,219    13.2   1,323   21.4   

  Percent in census tract with some college                                                                                        

   \<25%                                                21,117   34.6                              18,822   34.4   2,295   37.1   \<0.0001

   ≥25%                                                 39,885   65.4                              35,996   65.7   3,889   62.9   

  Percent in census tract living in poverty                                                                                        

   \<5%                                                 19,951   32.7                              18,276   33.3   1,675   27.1   \<0.0001

   5--7%                                                8,718    14.3                              7,919    14.5   799     12.9   

   8--12%                                               13,566   22.2                              12,177   22.2   1,389   22.5   

   \>12%                                                18,767   30.8                              16,446   30.0   2,321   37.5   

  Type of geographic area                                                                                                          

   Large metropolitan                                   34,481   56.5                              31,090   56.7   3,391   54.8   \<0.0001

   Metropolitan                                         17,568   28.8                              15,840   28.9   1,728   27.9   

   Urban                                                3,674    6.0                               3,242    5.9    432     7.0    

   Less urban/rural                                     5,279    8.7                               4,646    8.5    633     10.2   
  ------------------------------------------------------------------------------------------------------------------------------------------

###### 

Risk of undetected comorbidity.

                                                             OR                   95% CI   P value   
  ---------------------------------------------------------- -------------------- -------- --------- ----------
  Age at cancer diagnosis (years)                                                                     
   66--70                                                    Reference category                      
   71--75                                                    1.12                 1.02     1.22      0.02
   76--80                                                    1.28                 1.17     1.39      \<0.0001
   \>80                                                      1.53                 1.41     1.66      \<0.0001
  Race/ethnicity                                                                                      
   White                                                     Reference category                      
   Black                                                     1.04                 0.94     1.16      0.41
   Hispanic                                                  0.94                 0.81     1.08      0.39
   Other                                                     0.83                 0.71     0.97      0.02
  Year of cancer diagnosis                                                                            
   2001                                                      Reference category                      
   2002                                                      0.99                 0.91     1.07      0.75
   2003                                                      0.98                 0.90     1.07      0.68
   2004                                                      0.93                 0.85     1.01      0.08
   2005                                                      0.92                 0.84     1.00      0.05
  Index of prior comorbidity score (NCI Comorbidity Index)                                            
   0                                                         Reference category                      
   1                                                         1.20                 1.13     1.28      \<0.0001
   ≥2                                                        1.50                 1.38     1.63      \<0.0001
  Indicators of poor performance                                                                      
   0                                                         Reference category                      
   ≥1                                                        1.30                 1.21     1.40      \<0.0001
  Stage at diagnosis                                                                                  
    *In*   *situ*                                            Reference category                      
   I                                                         1.66                 1.49     1.85      \<0.0001
   II                                                        2.40                 2.15     2.67      \<0.0001
   III                                                       3.26                 2.87     3.71      \<0.0001
   IV                                                        5.51                 4.85     6.26      \<0.0001
  Histological grade                                                                                  
   Well differentiated                                       Reference category                      
   Moderately differentiated                                 1.11                 1.02     1.20      0.01
   Poorly differentiated                                     1.15                 1.05     1.26      \<0.01
   Undifferentiated/anaplastic                               1.25                 1.05     1.50      0.01
   Missing/unknown                                           1.14                 1.03     1.27      0.01
  Estrogen (ER) and progesterone (PR) receptor status                                                 
   ER and PR negative                                        Reference category                      
   ER or PR positive                                         1.05                 0.94     1.16      0.39
   ER and PR positive                                        1.00                 0.92     1.09      1.00
   Unknown/missing                                           1.14                 1.03     1.27      0.01
  Percent in census tract with some college                                                           
   \<25%                                                     Reference category                      
   ≥25%                                                      0.99                 0.93     1.05      0.70
  Percent in census tract living in poverty                                                           
   \<5%                                                      Reference category                      
   5--7%                                                     1.07                 0.98     1.17      0.12
   8--12%                                                    1.17                 1.08     1.27      \<0.0001
   \>12%                                                     1.34                 1.25     1.45      \<0.0001
  Type of geographic area                                                                             
   Large metropolitan                                        Reference category                      
   Metropolitan                                              0.97                 0.91     1.04      0.42
   Urban                                                     1.14                 1.02     1.28      0.02
   Less urban/rural                                          1.09                 0.99     1.20      0.08

OR: Odds Ratio; CI: Confidence Interval.

###### 

Adjuvant chemotherapy.

                                                             OR                   95% CI   *P* value   
  ---------------------------------------------------------- -------------------- -------- ----------- ----------
  Age at cancer diagnosis (years)                                                                      
   66--70                                                    Reference category                        
   71--75                                                    0.55                 0.51     0.59        \<0.0001
   76--80                                                    0.25                 0.23     0.27        \<0.0001
   \>80                                                      0.05                 0.04     0.05        \<0.0001
  Race/ethnicity                                                                                        
   White                                                     Reference category                        
   Black                                                     0.94                 0.84     1.05        0.27
   Hispanic                                                  1.15                 0.99     1.32        0.06
   Other                                                     1.13                 0.98     1.31        0.10
  Year of cancer diagnosis                                                                              
   2001                                                      Reference category                        
   2002                                                      0.95                 0.87     1.04        0.26
   2003                                                      0.86                 0.79     0.94        \<0.001
   2004                                                      0.88                 0.80     0.96        \<0.01
   2005                                                      0.79                 0.72     0.86        \<0.0001
  Index of prior comorbidity score (NCI Comorbidity Index)                                              
   0                                                         Reference category                        
   1                                                         0.96                 0.90     1.03        0.28
   ≥2                                                        0.74                 0.66     0.82        \<0.0001
  Index of undetected comorbidity score                                                                 
   0                                                         Reference category                        
   1                                                         0.81                 0.73     0.90        \<0.0001
   ≥2                                                        0.38                 0.30     0.49        \<0.0001
  Indicators of poor performance                                                                        
   0                                                         Reference category                        
   ≥1                                                        0.56                 0.51     0.62        \<0.0001
  Stage at diagnosis                                                                                    
   I                                                         Reference category                        
   II                                                        8.73                 8.17     9.34        \<0.0001
   III                                                       21.87                19.83    24.12       \<0.0001
  Histological grade                                                                                    
   Well differentiated                                       Reference category                        
   Moderately differentiated                                 1.58                 1.44     1.72        \<0.0001
   Poorly differentiated                                     2.54                 2.31     2.79        \<0.0001
   Undifferentiated/anaplastic                               2.01                 1.60     2.53        \<0.0001
   Missing/unknown                                           1.51                 1.33     1.71        \<0.0001
  Estrogen (ER) and progesterone (PR) receptor status                                                   
   ER and PR negative                                        Reference category                        
   Either ER or PR positive                                  0.32                 0.29     0.35        \<0.0001
   Both ER and PR positive                                   0.24                 0.22     0.26        \<0.0001
   Unknown/missing                                           0.30                 0.27     0.34        \<0.0001
  Percent in census tract with some college                                                             
   \<25%                                                     Reference category                        
   ≥25%                                                      1.02                 0.95     1.08        0.65
  Percent in census tract living in poverty                                                             
   \<5%                                                      Reference category                        
   5--7%                                                     0.93                 0.85     1.02        0.13
   8--12%                                                    0.93                 0.86     1.01        0.08
   \>12%                                                     0.91                 0.84     0.98        0.01
  Type of geographic area                                                                               
   Large metropolitan                                        Reference category                        
   Metropolitan                                              1.12                 1.05     1.20        \<0.01
   Urban                                                     1.14                 1.01     1.29        0.03
   Less urban/rural                                          1.06                 0.95     1.18        0.32

OR: Odds Ratio; CI: Confidence Interval.

###### 

Survival.

                                                             All-cause mortality   Cancer mortality   Other-cause mortality                                                                       
  ---------------------------------------------------------- --------------------- ------------------ ----------------------- ---------- ------- ------- -------- ---------- ------ ------ ------ ----------
  Age at cancer diagnosis (years)                                                                                                                                                                 
   66--70                                                    Reference category                                                                                                                   
   71--75                                                    1.34                  1.25               1.44                    \<0.0001   1.27    1.15    1.40     \<0.0001   1.55   1.36   1.75   \<0.0001
   76--80                                                    1.80                  1.68               1.93                    \<0.0001   1.47    1.34    1.62     \<0.0001   2.39   2.12   2.69   \<0.0001
   \>80                                                      3.41                  3.20               3.63                    \<0.0001   2.08    1.90    2.28     \<0.0001   5.74   5.15   6.41   \<0.0001
  Race/ethnicity                                                                                                                                                                                   
   White                                                     Reference category                                                                                                                   
   Black                                                     1.04                  0.97               1.11                    0.26       0.91    0.81    1.02     0.09       0.89   0.79   0.99   0.03
   Hispanic                                                  0.82                  0.74               0.91                    \<0.01     0.96    0.83    1.12     0.62       0.89   0.76   1.03   0.12
   Other                                                     0.79                  0.71               0.88                    \<0.0001   0.94    0.79    1.11     0.45       0.74   0.63   0.89   \<0.01
  Year of cancer diagnosis                                                                                                                                                                         
   2001                                                      Reference category                                                                                                                   
   2002                                                      0.99                  0.94               1.04                    0.63       0.98    0.90    1.07     0.67       0.99   0.92   1.06   0.67
   2003                                                      0.97                  0.92               1.02                    0.26       1.00    0.91    1.09     0.91       0.88   0.82   0.96   \<0.01
   2004                                                      0.91                  0.86               0.97                    \<0.01     0.90    0.82    0.99     0.03       0.87   0.79   0.95   \<0.01
   2005                                                      0.93                  0.87               1.00                    0.04       0.95    0.86    1.06     0.34       0.83   0.75   0.92   \<0.01
  Index of prior comorbidity score (NCI Comorbidity Index)                                                                                                                                         
   0                                                         Reference category                                                                                                                   
   1                                                         1.45                  1.39               1.52                    \<0.0001   1.18    1.10    1.27     \<0.0001   1.79   1.68   1.91   \<0.0001
   ≥2                                                        2.05                  1.95               2.16                    \<0.0001   1.34    1.22    1.47     \<0.0001   2.86   2.66   3.07   \<0.0001
  Index of undetected comorbidity score                                                                                                                                                            
   0                                                         Reference category                                                                                                                   
   1                                                         1.45                  1.38               1.53                    \<0.0001   1.32    1.21    1.43     \<0.0001   1.58   1.46   1.71   \<0.0001
   ≥2                                                        2.38                  2.18               2.60                    \<0.0001   1.67    1.43    1.95     \<0.0001   3.31   2.94   3.73   \<0.0001
  Indicators of poor performance                                                                                                                                                                   
   0                                                         Reference category                                                                                                                   
   ≥1                                                        1.80                  1.72               1.88                    \<0.0001   1.41    1.31    1.53     \<0.0001   2.15   2.02   2.29   \<0.0001
  Stage at diagnosis                                                                                                                                                                               
    *In*   *situ*                                            Reference category                                                                                                                   
   I                                                         1.79                  1.66               1.94                    \<0.0001   2.66    2.21    3.20     \<0.0001   1.44   1.31   1.60   \<0.0001
   II                                                        2.95                  2.73               3.19                    \<0.0001   7.88    6.59    9.41     \<0.0001   1.81   1.63   2.01   \<0.0001
   III                                                       6.03                  5.52               6.58                    \<0.0001   22.08   18.37   26.54    \<0.0001   2.52   2.21   2.86   \<0.0001
   IV                                                        16.72                 15.33              18.23                   \<0.0001   85.67   71.62   102.47   \<0.0001   2.62   2.21   3.10   \<0.0001
  Histological grade                                                                                                                                                                               
   Well differentiated                                       Reference category                                                                                                                   
   Moderately differentiated                                 1.11                  1.05               1.18                    \<0.01     1.37    1.22    1.54     \<0.0001   1.06   0.98   1.14   0.13
   Poorly differentiated                                     1.47                  1.39               1.56                    \<0.0001   2.28    2.02    2.56     \<0.0001   1.14   1.05   1.24   \<0.01
   Undifferentiated/anaplastic                               1.38                  1.23               1.56                    \<0.0001   2.24    1.83    2.74     \<0.0001   0.92   0.76   1.11   0.38
   Missing/unknown                                           1.30                  1.22               1.40                    \<0.0001   1.82    1.60    2.07     \<0.0001   1.13   1.02   1.24   0.02
  Estrogen (ER) and progesterone (PR) receptor status                                                                                                                                              
   ER and PR negative                                        Reference category                                                                                                                   
   Either ER or PR positive                                  0.69                  0.65               0.74                    \<0.0001   0.60    0.54    0.65     \<0.0001   0.91   0.81   1.01   0.07
   Both ER and PR positive                                   0.64                  0.60               0.67                    \<0.0001   0.44    0.40    0.47     \<0.0001   0.96   0.87   1.05   0.36
   Unknown/missing                                           0.87                  0.82               0.93                    \<0.0001   0.72    0.66    0.79     \<0.0001   1.13   1.02   1.26   0.02
  Percent in census tract with some college                                                                                                                                                        
   \<25%                                                     Reference category                                                                                                                   
   ≥25%                                                      1.03                  0.99               1.07                    0.15       1.05    0.99    1.12     0.09       1.08   1.02   1.15   0.01
  Percent in census tract living in poverty                                                                                                                                                        
   \<5%                                                      Reference category                                                                                                                   
   5--7%                                                     1.10                  1.03               1.16                    \<0.01     1.11    1.01    1.21     0.03       1.08   0.99   1.17   0.08
   8--12%                                                    1.06                  1.01               1.12                    0.03       0.98    0.90    1.06     0.59       1.03   0.96   1.11   0.40
   \>12%                                                     1.18                  1.12               1.24                    \<0.0001   1.05    0.97    1.14     0.25       1.06   0.99   1.14   0.10
  Type of geographic area                                                                                                                                                                          
   Large metropolitan                                        Reference category                                                                                                                   
   Metropolitan                                              1.07                  1.03               1.12                    \<0.01     0.99    0.92    1.06     0.70       0.99   0.93   1.05   0.71
   Urban                                                     0.97                  0.89               1.05                    0.38       0.81    0.70    0.93     \<0.01     0.76   0.67   0.86   \<0.0001
   Less urban/rural                                          1.07                  1.00               1.14                    0.05       1.03    0.93    1.15     0.56       1.03   0.94   1.14   0.55

HR: Hazard Ratio; CI: Confidence Interval.

[^1]: Academic Editor: Ian S. Fentiman
